The Observation Of Treatment Of Ligustrazine Combined With Bone Marrow Mesenchymal Stem Cells On Knee Osteoarthritis

Objective: Knee osteoarthritis(KOA) is common in the elderly frequently-occurring disease, seriously affect people’s live’s and health.We used ligustrazine and mesenchymal stem cells(BMSCs) as treatment for mild and moderate KOA,to observe the clinical effect and to explore its mechanism and to discuss the effective method.In order to provide a reliable clinical guiding recommendation and application of the treatment of KOA.Methods:There was an "random number chart" provided to the60patients which matched the selection criteria and randomly divided into Control group and Experimental group. Each group has given30cases. The Control group were treated with BMSCs injections and the Experimental group were treated with ligustrazine combined with BMSCs injections. All the patients were treated with BMSCs injections once a week (platelet lysate injection on the first and seventh days, and BMSCs injection on the forth day) as a course of treatment, one course a month, a total of three courses. The Experimental group were treated with ligustrazine one pill a time and twice a day, last for2weeks since the first infection as one course, a total of three courses. The two groups were observed the pretreatment and treatment after30days, and recorded the levels of two cytokines (lL-lβ,TNF-α) of synovial fluids and the WOMAC index. Finally, the experimental data were statistically analyzed.Results:1. Comparison of the WOMAC score, there are difference, P<0.05,which showed that the curative effect in treatment group was superior to control group.2. Comparison of clinical efficacy: the clinical effect had difference between control group and treatment group, P<0.05,which indicated the effect of the treatment group had certain superiority than that of control group.3.Comparison of reducing the content of1L-1β、TNF-α in the joint fluid of KOA patients:there are differences, P<0.05,which indicated that the curative effect in treatment group was superior to control group.Conclusion:The treatment of ligustrazine combine with BMSCs can reduce the level of IL-1β、TNF-α in the joint synovial fluid, improve clinical symptoms in patients with KOA, then treat the patients with mild-to-moderate KOA.At the same time has advantages of easy operation and small side reaction.